Literature DB >> 15686959

Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity.

Elizabeth S McDonald1, Kelli R Randon, Andrew Knight, Anthony J Windebank.   

Abstract

Cisplatin causes apoptosis of dorsal root ganglia (DRG) neurons. The amount of platinum binding to DNA correlates with cisplatin toxicity in cancer cellsGenomic DNA platinum content of cultured embryonic DRG neurons and PC12 cells was assayed using inductively coupled plasma mass spectrometry (ICP-MS). Throughout these studies, "cisplatin" refers to the specific drug; "platinum" to the bound form of the drug that is measured in ICP-MS.. Cisplatin binds neuronal DNA more than a neuron-like dividing cell line (PC12); 10-fold at 24 h and 24-fold greater at 72 h. Difference in platinum accumulation was not due to dividing versus post-mitotic state, or to a difference in rate of repair. There was overall greater accumulation of platinum in DRG neurons. In vivo DNA-Platinum binding in adult (300 g) rat DRG was greater than in multiple other tissues. Concomitant treatment with high-dose NGF prevented cisplatin-mediated neuronal apoptosis in vitro but did not reduce adduct formation. Our results show that NGF does not alter platination of DNA, indicating that it interrupts the platinum death pathway after adduct formation. In addition, disproportionate platinum accumulation may explain why a drug aimed at killing rapidly dividing cells causes sensory neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15686959     DOI: 10.1016/j.nbd.2004.09.013

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  92 in total

1.  Drosophila melanogaster: a new model to study cisplatin-induced neurotoxicity.

Authors:  Jewel L Podratz; Nathan P Staff; Dara Froemel; Anna Wallner; Florian Wabnig; Allan J Bieber; Amy Tang; Anthony J Windebank
Journal:  Neurobiol Dis       Date:  2011-04-15       Impact factor: 5.996

2.  Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.

Authors:  Iryna A Khasabova; Sergey Khasabov; Justin Paz; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

3.  Alpha-lipoic acid and frataxin: a new indication for an old antioxidant?

Authors:  James W Russell
Journal:  Exp Neurol       Date:  2009-04-15       Impact factor: 5.330

4.  Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons.

Authors:  Yanlin Jiang; Chunlu Guo; Michael R Vasko; Mark R Kelley
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 5.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

Review 6.  Emerging trends in understanding chemotherapy-induced peripheral neuropathy.

Authors:  Jérémy Ferrier; Vanessa Pereira; Jérome Busserolles; Nicolas Authier; David Balayssac
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 7.  [Long-term toxicity after therapy for testicular cancer with special focus on sexual disorders].

Authors:  J Oldenburg; S D Fosså
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

Review 8.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

Authors:  Abolfazl Avan; Tjeerd J Postma; Cecilia Ceresa; Amir Avan; Guido Cavaletti; Elisa Giovannetti; Godefridus J Peters
Journal:  Oncologist       Date:  2015-03-12

9.  Cisplatin-mediated activation of extracellular signal-regulated kinases 1/2 (ERK1/2) by inhibition of ERK1/2 phosphatases.

Authors:  Agata Gozdz; Aruna Vashishta; Katarzyna Kalita; Erzsebet Szatmari; Jing-Juan Zheng; Shigeo Tamiya; Nicholas A Delamere; Michal Hetman
Journal:  J Neurochem       Date:  2008-07-04       Impact factor: 5.372

10.  Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase.

Authors:  Elizabeth W LaPensee; Sandy J Schwemberger; Christopher R LaPensee; El Mustapha Bahassi; Scott E Afton; Nira Ben-Jonathan
Journal:  Carcinogenesis       Date:  2009-05-14       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.